NCT06151847 2024-02-28
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Unknown
Clinical Trials
71 trialsNCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT06182735 2023-12-27
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma
Fudan University
Phase 1 Unknown
NCT04217278 2023-05-10
COSI
University of Birmingham
Phase 2/3 Unknown
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05798546 2023-04-04
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
Phase 1 Unknown
NCT05776407 2023-03-20
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Chongqing University Cancer Hospital
Phase 1/2 Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04706936 2023-02-06
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05665114 2023-01-03
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Phase 1 Unknown
NCT05654077 2022-12-19
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT05616468 2022-12-15
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT01946373 2022-10-04
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Karolinska University Hospital
Phase 1 Unknown
NCT05515185 2022-08-25
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
The First People's Hospital of Lianyungang
Phase EARLY_PHASE1 Unknown
NCT05379647 2022-05-18
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
Phase 1 Unknown
NCT05322733 2022-04-19
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04823091 2022-03-16
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT04112589 2022-03-14
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
PETHEMA Foundation
Phase 1/2 Unknown
NCT05008536 2021-11-23
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT05084027 2021-10-27
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT05016063 2021-08-23
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT03814447 2021-08-10
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
Shanghai 6th People's Hospital
Phase EARLY_PHASE1 Unknown
NCT04264078 2021-06-28
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04796675 2021-04-08
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT04796688 2021-03-15
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT00790413 2021-02-21
Haploidentical Stem Cell Transplantation in Neuroblastoma
Lund University Hospital
Phase EARLY_PHASE1 Unknown
NCT03380039 2020-10-12
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase NA Unknown
NCT03302403 2020-10-08
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
First Affiliated Hospital of Wenzhou Medical University
Phase NA Unknown
NCT03716856 2020-10-08
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
First Affiliated Hospital of Zhejiang University
Phase 1 Unknown
NCT04221971 2020-10-01
NK Cell Infusion for Patients With Acute Myeloid Leukemia
Peking University People's Hospital
Phase 1 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT04264039 2020-02-11
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT03110640 2019-11-27
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
First Affiliated Hospital of Wenzhou Medical University
Phase 1 Unknown
NCT04037566 2019-07-30
CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
Xijing Hospital
Phase 1 Unknown
NCT04008888 2019-07-05
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT03916679 2019-04-16
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT03799913 2019-04-10
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT03029273 2019-01-17
NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
NCT02366546 2018-10-24
Investigator Initiated Phase 1 Study of TBI-1301
Mie University
Phase 1 Unknown
NCT02333838 2018-08-13
TBF-Cord
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03335241 2017-11-13
Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT03208556 2017-09-14
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
Peking University
Phase 1 Unknown
NCT03171220 2017-06-06
NRT-01
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Unknown
NCT03146533 2017-05-17
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
Shenzhen Second People's Hospital
Phase 1/2 Unknown
NCT03044743 2017-05-02
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Unknown
NCT03084380 2017-03-20
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
Xinqiao Hospital of Chongqing
Phase 1/2 Unknown
NCT02685670 2017-03-16
MatchCART
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Phase 1/2 Unknown